mesna 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1711	3375-50-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mesna mercaptoethanesulfonic acid reduced coenzyme M	A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. Molecular weight: 142.19 Formula: C2H6O3S2 CLOGP: -1.55 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 54.37 ALOGS: -1.05 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mesna
mercaptoethanesulfonic acid
reduced coenzyme M

A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.

Molecular weight: 142.19
Formula: C2H6O3S2
CLOGP: -1.55
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 54.37
ALOGS: -1.05
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.20	g	Inhal.solution

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	62 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	28.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	20.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	0.65 L/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.36 hours	Lombardo F, Berellini G, Obach RS

Showing 1 to 6 of 6 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1988	FDA	BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	685.65	24.11	331	8461	118118	63362112
Encephalopathy	407.63	24.11	165	8627	38455	63441775
Mucosal inflammation	254.87	24.11	126	8666	46802	63433428
Pancytopenia	209.70	24.11	143	8649	96790	63383440
Neutropenia	204.54	24.11	179	8613	174826	63305404
Pyrexia	145.19	24.11	244	8548	470234	63009996
Cystitis haemorrhagic	109.69	24.11	35	8757	4088	63476142
Thrombocytopenia	105.80	24.11	117	8675	151040	63329190
Neurotoxicity	102.25	24.11	49	8743	16941	63463289
Leukopenia	93.92	24.11	81	8711	77209	63403021

Showing 1 to 10 of 55 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	682.42	21.70	452	10012	136397	34810070
Encephalopathy	286.35	21.70	160	10304	35159	34911308
Cystitis haemorrhagic	152.13	21.70	59	10405	5620	34940847
Pyrexia	142.40	21.70	309	10155	332704	34613763
Neutropenia	129.30	21.70	194	10270	156584	34789883
Mucosal inflammation	123.38	21.70	98	10366	38524	34907943
Venoocclusive liver disease	107.70	21.70	51	10413	7915	34938552
Cytokine release syndrome	90.55	21.70	66	10398	22811	34923656
Aplastic anaemia	89.58	21.70	48	10416	9668	34936799
Pancytopenia	80.02	21.70	119	10345	95038	34851429

Showing 1 to 10 of 52 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1242.72	19.95	720	17076	230279	79496313
Encephalopathy	639.43	19.95	308	17488	67089	79659503
Mucosal inflammation	312.41	19.95	200	17596	75380	79651212
Pancytopenia	307.24	19.95	271	17525	165474	79561118
Neutropenia	294.77	19.95	341	17455	287369	79439223
Pyrexia	260.61	19.95	507	17289	678202	79048390
Cystitis haemorrhagic	252.78	19.95	90	17706	9082	79717510
Febrile bone marrow aplasia	165.38	19.95	73	17723	12947	79713645
Aplastic anaemia	157.93	19.95	78	17718	17827	79708765
Thrombocytopenia	143.55	19.95	231	17565	265028	79461564

Showing 1 to 10 of 120 entries

Previous1 2 3 4 5…12Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	R05CB05	RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS Mucolytics
ATC	V03AF01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment
CHEBI has role	CHEBI:23354	coenzymes
MeSH PA	D020011	Protective Agents

Showing 1 to 4 of 4 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Testicular Germ Cell Tumor	indication
Prevention of Chemotherapy-Induced Hemorrhagic Cystitis	indication
Ewing's sarcoma	off-label use	76909002	DOID:3369
Burkitt's lymphoma	off-label use	118617000
Non-small cell lung cancer	off-label use	254637007	DOID:3908
Malignant tumor of head and/or neck	off-label use	255056009
Osteosarcoma of bone	off-label use	307576001	DOID:3376
Soft or Connective Tissue Sarcoma	off-label use
Renal tubular acidosis	contraindication	1776003	DOID:14219
Hyperbilirubinemia	contraindication	14783006	DOID:2741

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.61	acidic
pKa2	9.77	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
002678	NDDF
108821000	SNOMEDCT_US
1546354	RXNORM
19767-45-4	SECONDARY_CAS_RN
23662354	PUBCHEM_CID
2813	INN_ID
386922000	SNOMEDCT_US
4019477	VUID
4019477	VANDF
41498	MMSL

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
mesna	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9260	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	25 sections
MESNA	HUMAN PRESCRIPTION DRUG LABEL	1	10019-951	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	26 sections
MESNA	HUMAN PRESCRIPTION DRUG LABEL	1	10019-951	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	26 sections
MESNA	HUMAN PRESCRIPTION DRUG LABEL	1	10019-953	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	26 sections
MESNA	HUMAN PRESCRIPTION DRUG LABEL	1	10019-953	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	26 sections
Mesna	HUMAN PRESCRIPTION DRUG LABEL	1	25021-201	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	26 sections
mesna	HUMAN PRESCRIPTION DRUG LABEL	1	62778-304	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	2 sections
Mesna	Human Prescription Drug Label	1	63323-733	INJECTION, SOLUTION	100 mg	INTRAVENOUS	ANDA	27 sections
Mesna	Human Prescription Drug Label	1	68083-161	SOLUTION	100 mg	INTRAVENOUS	ANDA	26 sections
Mesna	Human Prescription Drug Label	1	68083-161	SOLUTION	100 mg	INTRAVENOUS	ANDA	26 sections

Showing 1 to 10 of 17 entries

Previous1 2Next